JPRN-jRCT2080221837未知1 期
A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients diagnosed with lung cancer who have not responded to prior therapy or have become worse.
- •- Patients who have overall good general conditions.
- •- Patients who have at least one lesion that can be accurately assessed by imaging.
- •- Patients who have appropriate renal conditions confirmed by test results for taking part in the study.
- •- Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status.
排除标准
- •- Patients with brain metastases or spinal cord compression.
- •- Patients with significant abnormal ECG findings.
- •- Patients with evidence of severe or uncontrolled systemic disease.
- •- The main organ functional test values for bone marrow, kidney, and liver, etc., do not meet the standards.
- •- Patients with known hypersensitivity to docetaxel or products containing polysorbate 80.
研究者
相似试验
未知
1 期
A Phase 1, 2, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinomanresectable Locally Advanced or Metastatic, Medullary Thyroid CarcinomaJPRN-jRCT2080221951AstraZeneca
已完成
1 期
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Relapsed/Refractory (R/R) Higher Risk Myelodysplastic Syndrome (MDS)JPRN-jRCT1080224851Astellas Pharma Global Development, Inc.43
已完成
1 期
A Study of Lazertinib as Monotherapy or in Combination with Amivantamab in Participants with Advanced Non-small Cell Lung CancerJPRN-jRCT2080224850Janssen Pharmaceutical K.K.520
已完成
1 期
A Phase I, Randomised, Open Label Study of the Safety, Tolerability and Pharmacokinetics of Single Sublingual or Oral Dose of GDN-1 in Adult Healthy Volunteers.This trial is to assess the tolerability and pharmacokinetics in healthy adult volunteers and does not focus on any particular health condition or problem.Subsequent studies are planned to evaluate efficacy in promoting improved exercise endurance and recovery, reduced muscle damage and soreness post exercise and for its lipid lowering effects in appropriate populations.This trial is to assess the tolerability and pharmacokinetics in healthy adult volunteers and does not focus on any particular health condition or problem.Subsequent studies are planned to evaluate efficacy in promoting improved exercise endurance and recovery, reduced muscle damage and soreness post exercise and for its lipid lowering effects in appropriate populations.Other - Research that is not of generic health relevance and not applicable to specific health categories listed aboveACTRN12615000560594Gordagen Pharmaceuticals Pty Ltd60
进行中（未招募）
不适用
A clinical trial to test the safety of Cell Bandage, a product made from the patient's own bone marrow stem cells, in the treatment of meniscus (cartilage) tears in the kneeEUCTR2010-024162-22-GBAzellon Ltd10